Compare Regeneron Pharmaceuticals Inc (REGN) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Banco Santander SA trades at $13.5 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 2.5× Regeneron Pharmaceuticals Inc's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Banco Santander SA for 55 Days on average.
| REGN | SAN | |
|---|---|---|
Market Cap | $76.14B | $192.86B |
Volume | 500,239 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $852.03 | $15.05 |
52-Week Low | $557.73 | $9.65 |
Typical Hold Time | 107 Days | 55 Days |
Enterprise Value | $70.85B | $360.86B |
Dividend Yield | 0.51% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Banco Santander (SAN) trades at $13.66, down 2.5% with bearish technical signals despite strong profitability metrics including 26.25% net margin and 16.07% ROE. The company completed its Webster Financial acquisition in August 2026, expanding U.S. presence while reporting record quarterly profits. Cash flow trends show recent operational challenges with negative $28.13B net cash flow in 2024, though revenue growth remains steady at $60.02B for 2025.
SAN presents a mixed outlook with strong fundamental performance offset by technical weakness. The acquisition-driven growth strategy and technological transformation support long-term value, but negative cash flows and high debt levels ($288.23B long-term debt) pose execution risks. Analyst consensus remains moderately bullish with 64% buy ratings, suggesting potential upside if operational efficiency improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
